Jupiter Asset Management Ltd. raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 110.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,569,027 shares of the biopharmaceutical company's stock after acquiring an additional 822,518 shares during the period. Jupiter Asset Management Ltd.'s holdings in Pfizer were worth $39,759,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. LSV Asset Management boosted its holdings in shares of Pfizer by 10.2% in the 1st quarter. LSV Asset Management now owns 15,153,114 shares of the biopharmaceutical company's stock valued at $383,980,000 after purchasing an additional 1,400,622 shares in the last quarter. Mirabaud & Cie SA boosted its holdings in shares of Pfizer by 9.9% in the 1st quarter. Mirabaud & Cie SA now owns 12,779 shares of the biopharmaceutical company's stock valued at $324,000 after purchasing an additional 1,150 shares in the last quarter. Endeavor Private Wealth Inc. boosted its holdings in shares of Pfizer by 969.2% in the 1st quarter. Endeavor Private Wealth Inc. now owns 9,345 shares of the biopharmaceutical company's stock valued at $237,000 after purchasing an additional 8,471 shares in the last quarter. Signature Wealth Management Partners LLC increased its holdings in shares of Pfizer by 113.9% during the first quarter. Signature Wealth Management Partners LLC now owns 16,529 shares of the biopharmaceutical company's stock worth $419,000 after buying an additional 8,800 shares in the last quarter. Finally, Baker Avenue Asset Management LP increased its holdings in shares of Pfizer by 9.9% during the first quarter. Baker Avenue Asset Management LP now owns 28,727 shares of the biopharmaceutical company's stock worth $728,000 after buying an additional 2,596 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Stock Up 0.9%
Pfizer stock opened at $23.49 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.32. The firm's fifty day moving average is $24.36 and its 200 day moving average is $24.58. The company has a market capitalization of $133.55 billion, a PE ratio of 17.02, a PEG ratio of 0.84 and a beta of 0.52.
Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the company earned $0.82 EPS. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer's dividend payout ratio is presently 124.64%.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. BMO Capital Markets cut their price target on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Morgan Stanley lifted their price target on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. TD Cowen cut their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. Finally, UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.28.
Get Our Latest Stock Report on PFE
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.